Ocuphire Pharma, Inc. announced that it has entered into common stock purchase agreement with new investor Lincoln Park Capital Fund, LLC, a fund managed by Lincoln Park Capital, LLC to issue common shares for the gross proceeds of $50,000,000 on August 10, 2023. Upon the execution of the Purchase Agreement, the Company issued 246,792 shares of common stock to Lincoln Park and paid Lincoln Park $40,000, which together represents the fee for Lincoln Park?s commitment to purchase shares of the Company?s common stock under the Purchase Agreement. The investor can purchase up to $50,000,000 common shares over a 30-month period at prices per share as computed under the Purchase Agreement.